Buynetmeds.com has been sent a warning letter over the sale of opoioids and weight-loss drugs without a prescription.

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

More than 1% of U.S. children between the ages of 2 and 18 had “extremely severe obesity” in 2023 — a 250% increase from 2008 ...

Key Points It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high.Shares of Novo ...

We can't have it both ways. If we want more cutting-edge drugs, we have to protect the property rights that make them ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

A study reveals potentially fatal side effects of GLP-1 drugs, that people are using to lose weight. It’s well known that ...

With their lengthening laundry list of health benefits, drugs like Ozempic are showing promise for people who struggle with addiction.

Novo Nordisk A/S (NYSE: NVO) is one of the high-margin pharma stocks to buy now. Berenberg has reaffirmed its Hold rating on ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Albertsons CEO Susan Morris said she had to "double-check the numbers" when she saw how much cottage cheese the chain was ...